Alpha Cognition (ACOG) Competitors $8.00 -1.99 (-19.92%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock ACOG vs. KURA, ORKA, RAPP, SAGE, PGEN, SLDB, OPT, SEPN, RZLT, and TERNShould you be buying Alpha Cognition stock or one of its competitors? The main competitors of Alpha Cognition include Kura Oncology (KURA), Oruka Therapeutics (ORKA), Rapport Therapeutics (RAPP), Sage Therapeutics (SAGE), Precigen (PGEN), Solid Biosciences (SLDB), Opthea (OPT), Septerna (SEPN), Rezolute (RZLT), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. Alpha Cognition vs. Its Competitors Kura Oncology Oruka Therapeutics Rapport Therapeutics Sage Therapeutics Precigen Solid Biosciences Opthea Septerna Rezolute Terns Pharmaceuticals Kura Oncology (NASDAQ:KURA) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Do analysts prefer KURA or ACOG? Kura Oncology currently has a consensus price target of $24.10, indicating a potential upside of 265.15%. Alpha Cognition has a consensus price target of $20.00, indicating a potential upside of 150.00%. Given Kura Oncology's higher probable upside, equities research analysts clearly believe Kura Oncology is more favorable than Alpha Cognition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor KURA or ACOG? In the previous week, Kura Oncology had 8 more articles in the media than Alpha Cognition. MarketBeat recorded 17 mentions for Kura Oncology and 9 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 0.52 beat Kura Oncology's score of -0.10 indicating that Alpha Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Cognition 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, KURA or ACOG? Alpha Cognition has lower revenue, but higher earnings than Kura Oncology. Alpha Cognition is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$53.88M10.63-$173.98M-$2.26-2.92Alpha CognitionN/AN/A-$14.64M-$1.20-6.67 Which has more risk & volatility, KURA or ACOG? Kura Oncology has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500. Is KURA or ACOG more profitable? Kura Oncology's return on equity of -52.32% beat Alpha Cognition's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -52.32% -29.59% Alpha Cognition N/A -65.83%-48.21% SummaryKura Oncology beats Alpha Cognition on 8 of the 13 factors compared between the two stocks. Get Alpha Cognition News Delivered to You Automatically Sign up to receive the latest news and ratings for ACOG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACOG vs. The Competition Export to ExcelMetricAlpha CognitionMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$160.04M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-6.6720.4930.2725.74Price / SalesN/A356.37469.95115.79Price / CashN/A43.0338.2159.48Price / Book3.098.608.846.15Net Income-$14.64M-$54.65M$3.25B$265.06M7 Day Performance-19.19%5.86%3.71%2.60%1 Month Performance-23.08%8.86%5.85%2.83%1 Year PerformanceN/A13.33%30.25%25.58% Alpha Cognition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACOGAlpha Cognition1.7652 of 5 stars$8.00-19.9%$20.00+150.0%N/A$160.04MN/A-6.67N/ANews CoverageEarnings ReportHigh Trading VolumeKURAKura Oncology4.0203 of 5 stars$6.42+1.6%$24.50+281.6%-65.3%$556.73M$53.88M-3.06130News CoverageORKAOruka Therapeutics2.964 of 5 stars$14.47+1.2%$40.38+179.0%N/A$545.31MN/A-3.23N/ANews CoverageEarnings ReportAnalyst ForecastAnalyst RevisionRAPPRapport Therapeutics1.7749 of 5 stars$14.93+6.3%$28.00+87.5%-26.8%$544.95MN/A-4.33N/AAnalyst RevisionSAGESage Therapeutics3.9351 of 5 stars$8.68flat$8.02-7.7%N/A$543.54M$41.24M-1.78690Positive NewsPGENPrecigen4.0601 of 5 stars$1.81+2.6%$6.00+232.4%+65.2%$535.75M$4.20M-3.24190News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionSLDBSolid Biosciences3.5248 of 5 stars$6.89+1.0%$15.10+119.3%-26.1%$532.88M$8.09M-2.30100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionOPTOpthea0.4103 of 5 stars$3.41+7.2%$1.33-60.9%+47.6%$524.83M$120K0.008News CoverageGap UpHigh Trading VolumeSEPNSepterna1.7447 of 5 stars$11.56-2.4%$26.75+131.4%N/A$518.90M$1.08M0.00N/ANews CoverageEarnings ReportUpcoming EarningsAnalyst RevisionRZLTRezolute3.2095 of 5 stars$5.91+0.2%$11.83+100.2%+48.5%$515.39MN/A-5.1540TERNTerns Pharmaceuticals4.0373 of 5 stars$5.79+0.7%$15.63+169.9%+4.3%$505.70MN/A-5.3140 Related Companies and Tools Related Companies KURA Competitors ORKA Competitors RAPP Competitors SAGE Competitors PGEN Competitors SLDB Competitors OPT Competitors SEPN Competitors RZLT Competitors TERN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACOG) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpha Cognition Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alpha Cognition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access